

Editorial



The Human Microbiome: A New Frontier in Precision Medicine

Doi: <https://doi.org/10.3329/kyamcj.v16i02.87129>

Introduction

The human microbiome has emerged as a critical determinant of health and disease. Recent advances in metagenomics, systems biology, and multi-omics technologies have illuminated the profound influence of the microbiome on immunity, metabolism, drug response, and disease susceptibility. In the context of precision medicine, the microbiome represents a transformative frontier, offering novel biomarkers for early diagnosis and personalized interventions. Its dynamic and modifiable nature holds a great promise across a spectrum of conditions, including cancer, metabolic disorders, autoimmune diseases, and neuropsychiatric illnesses.¹ Precision medicine, also known as personalized medicine, is revolutionizing healthcare by moving away from the “one-size-fits-all” model toward individualized strategies for disease prevention, diagnosis, and treatment. At its core, personalized medicine integrates cutting-edge tools like genomic sequencing, biomarker testing, and big data analytics to provide clinicians with detailed insights into the molecular basis of disease in each patient. This enables the development of therapies that are more effective, with fewer side effects, and tailored preventive measures considering individual’s risk factors.² Although genetics has historically been regarded as the foundation of personalized medicine, emerging evidence underscores the human microbiome (the diverse consortium of microorganisms residing within the body) as a significant and dynamic contributor to individualized healthcare. Once considered a passive bystander, human microbiome has emerged as a dynamic partner in health and disease in recent years.³ Beyond reflecting our bodily condition, microbiome actively directs key functions like metabolism, immunity, pharmacokinetics and behavior. As such, the microbiome represents both a biomarker and therapeutic target in the next era of precision medicine. With advances in next-generation sequencing, metagenomics, and systems biology, the microbiome is now positioned at the forefront of precision medicine, offering new avenues for diagnosis, prognosis, and therapy tailored to the individual.⁴ This editorial explores how the microbiome is reshaping our understanding of disease pathophysiology and outlines its future in personalized healthcare.

The Microbiome: A Personalized Signature

Each individual harbors a unique microbial fingerprint that interacts continuously with host systems. The composition and function of an individual’s microbiota are shaped by a variety of factors, influenced by genetics, age, diet, geographical location, antibiotic exposure, and environmental interactions. These microbial communities help digest complex polysaccharides, produce vitamins, send neuroendocrine signals, and regulate the immune system. They also protect against harmful pathogens and influence how drugs are processed in the body. These microbiota-host interactions have unveiled new biomarkers and therapeutic targets in diseases ranging from inflammatory bowel disease to cancer, diabetes, and neuropsychiatric disorders.⁵ This complex and individualized interplay between microbiome and host underscores the potential of microbiome data in tailoring interventions with greater accuracy.

Clinical Implications of Microiome in Precision Medicine

(a) Disease risk stratification: Gut mycobiota dysbiosis (alterations in the microbiome) has been linked to many diseases within and outside the intestine. Dysbiosis can predict risk for diseases like colorectal cancer, inflammatory bowel disease (IBD), type 2 diabetes, neurodegenerative conditions such as Parkinson’s and Alzheimer’s, obesity and metabolic syndrome long before clinical symptoms arise.^{5, 6} Identifying microbial changes before symptoms appear highlights the microbiome as a possible early disease marker. Microbiome-based diagnostic tests are being developed by applying machine learning algorithms of gut microbiome profiles for early detection of diseases (e.g., microbiome-derived biomarkers in stool for colorectal cancer screening).

(b) Therapeutic applications: The therapeutic applications of precision medicine represent one of the most impactful shifts in modern healthcare. The interaction between drugs and the microbiome is termed as pharmacomicrobiomics that has major implications for precision therapy. For example, gut microbes can metabolize levodopa, altering its availability in Parkinson’s disease. Similarly, composition of microbiota impacts response to immune checkpoint inhibitors in cancer therapy. Fecal microbiota transplantation (FMT) approaches are being trialed to restore healthy microbial balance in conditions like *Clostridioi-des difficile* infections and is also being explored in ulcerative colitis, autism, and resistant infections. Personalized healthcare is increasingly exploring strategies that match donors and recipients based on microbial compatibility. Emerging strategies involve customizing probiotics and postbiotics to each person’s microbiome in order to fine-tune biological processes like control of inflammation and insulin sensitivity.^{6, 7}

(c) Microbiome in oncology: The gut microbiota has a profound impact on cancer development, progression, and treatment outcomes. By integrating microbial profiling into oncology, clinicians can better stratify patients, anticipate side effects, and personalize treatment regimens.⁸ Certain microbial signatures predict better outcomes with immunotherapy. Microbial metabolites can either promote or inhibit tumor growth. The gut microbiome has been associated with immune checkpoint inhibitor (ICI) efficacy and microbial composition may guide cancer immunotherapy strategies to improve outcomes and minimize toxicity.⁹

Challenges to Integrate the Microbiome into Precision Medicine

Despite its promise, integrating microbiome data into clinical practice faces several challenges. First, microbiome data are highly variable across individuals and over time, influenced by diet, environment, medications, and sampling methods, which complicates standardization and reproducibility. Second, inconsistent sampling and analysis practices make it difficult to reproduce findings and compare studies. Third, telling cause from correlation is difficult, and many microbiome–disease links may be secondary or context-specific. Fourth, clinical translation is constrained by limited validated biomarkers, small and heterogeneous cohorts, and insufficient longitudinal data

linking microbiome changes to outcomes. Fifth, regulatory and ethical issues such as data privacy, consent for longitudinal and multi-omic profiling, and oversight for live biotherapeutic products are still evolving. Sixth, integrating microbiome data with genomics, metabolomics, clinical records, and lifestyle information requires robust computational infrastructure, interoperable data standards, and interpretable models that clinicians can trust. Finally, equitable access and representation are concerns, as most datasets are derived from limited populations, risking biased tools and unequal benefits from microbiome-guided care.¹⁰

Opportunities and Future Directions

The microbiome offers major opportunities to enhance precision medicine through earlier detection, individualized therapies, and better prediction of treatment response. Near-term advances include standardized multi-omic profiling (metagenomics, metatranscriptomics, metabolomics) to build robust, longitudinal reference maps that link microbial functions to clinical phenotypes. These datasets can power AI models to stratify patients, forecast disease trajectories, and guide tailored interventions such as diet, prebiotics, probiotics, postbiotics, synbiotics, and targeted antimicrobials. Pharmacomicrobiomics aims to fine-tune dosing and curb toxicity by incorporating how microbes metabolize medications. Engineered microbes and microbiome-targeted therapeutics (including precision bacteriophages and next-generation live biotherapeutic products) open avenues for site-specific, mechanism-driven treatments. Noninvasive microbiome biomarkers from stool, saliva, skin, and vaginal samples could support routine screening and ongoing monitoring in both clinical settings and at home. Combining microbiome data with genomics, immune profiles, and environmental factors can enable systems-level decision support. Harmonized clinical pipelines, regulatory frameworks specific to live biotherapeutic products, and iterative learning health systems collectively enable scalable translation of microbiome insights into practice.^{11,12}

Conclusion

The human microbiome is not merely an adjunct to human biology, rather it is a clinical imperative and co-architect of health. With the shift toward a holistic, individualized model of precision medicine, incorporating microbiome science promises to redefine disease understanding, risk prediction, and therapeutic strategies. Understanding and harnessing this internal ecosystem may hold the key to truly individualized care. Precision medicine, when informed by the microbiome, offers a path toward interventions that are not only personalized, but also preventive, predictive, and participatory. The path forward lies in translating microbiome research into actionable clinical insights, thereby redefining prevention, diagnosis, and therapy for the 21st century. Personalized medicine marks a paradigm shift in individual healthcare by leveraging genetic, molecular, and environmental data to offer more accurate diagnoses, targeted therapies, and personalized preventive care.

References

1. El Jaddaoui I, Sehli S, Al Idrissi N, Bakri Y, Belyamani L, Ghazal H. The Gut Mycobiome for Precision Medicine. *Journal of Fungi*. 2025;11(4):279. <https://doi.org/10.3390/jof11040279>
2. Stefanicka- Wojtas D, Kurpas D. Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions). *Journal of Personalized Medicine*. 2023; 13(3):380. <https://doi.org/10.3390/jpm13030380>
3. Afzaal M, Saeed F, Shah YA, Hussain M, Rabail R, Socol CT, et al. Human gut microbiota in health and disease: Unveiling the relationship. *Front. Microbiol*. 2022;13: <https://doi.org/10.3389/fmicb.2022.999001>
4. Dakal TC, Xu C, Kumar A. Advanced computational tools, artificial intelligence and machine-learning approaches in gut microbiota and biomarker identification. *Front. Med. Technol*. 2025;6. <https://doi.org/10.3389/fmedt.2024.1434799>
5. Zhang H, Lee BJY, Wang T, Xiang X, Tan Y, Han Y, et al. Microbiota, chronic inflammation, and health: The promise of inflammatome and inflammatomics for precision medicine and health care. *hLife*. 2025;3:307-326. <https://doi.org/10.1016/j.hlife.2025.04.004>
6. El Jaddaoui I, Sehli S, Al Idrissi N, Bakri Y, Belyamani L, Ghazal H. The Gut Mycobiome for Precision Medicine. *Journal of Fungi*. 2025;11(4):279. <https://doi.org/10.3390/jof11040279>
7. Yaqub MO, Jain A, Joseph CE, Edison LK. Microbiome-Driven Therapeutics: From Gut Health to Precision Medicine. *Gastrointestinal Disorders*. 2025; 7(1):7. <https://doi.org/10.3390/gidisord7010007>
8. Nobels A, van Marcke C, Jordan BF, Hul MV, Cani PD. The gut microbiome and cancer: from tumorigenesis to therapy. *Nature Metabolism*. 2025;7:895–917. <https://doi.org/10.1038/s42255-025-01287-w>
9. Verheijden RJ, van Eijs MJM, Paganelli FL, van de Wijgert JHHM, Suijkerbuijk KPM. Gut microbiome and immune checkpoint inhibitor toxicity. *European Journal of Cancer*. 2025;216: 115221. <https://doi.org/10.1016/j.ejca.2025.115221>
10. Kumar B, Lorusso E, Fosso B, Pesole G. A comprehensive overview of microbiome data in the light of machine learning applications: categorization, accessibility, and future directions. *Front. Microbiol*. 2024;15. <https://doi.org/10.3389/fmicb.2024.1343572>
11. Rahmati R, Zarimeidani F, Boroujeni MRG, Sadighbathi S, Kashaniasl Z, Saleh M, et al. CRISPR-Assisted Probiotic and In Situ Engineering of Gut Microbiota: A Prospect to Modification of Metabolic Disorders. *Probiotics & Antimicro. Prot*. 2025. <https://doi.org/10.1007/s12602-025-10561-y>
12. Yaqub MO, Jain A, Joseph CE, Edison LK. Microbiome-Driven Therapeutics: From Gut Health to Precision Medicine. *Gastrointestinal Disorders*. 2025; 7(1):7. <https://doi.org/10.3390/gidisord7010007>

Prof. Dr. Md. Abdus Salam

Dean, Faculty of Biotechnology and Biomedical Engineering,
Rajshahi Medical University